Simmunome Inc
Teaching Machines to Accurately Mimic Disease
- Stage Prototype Ready
- Industry Biotechnology
- Location Montreal, QC, Canada
- Currency CAD
- Founded February 2018
- Employees 2
- Incorporation Type C-corp
- Website simmunome.com
Company Summary
Simmunome will construct AI driven computational models based on our proprietary disease frameworks. These disease models will be used for:
i) Discovery of novel targets and repurposing therapeutic candidates, which will be sold to clients through licensing deals
ii) Pre-clinical simulations using proprietary endpoints to define the likelihood of success of drug targets; this will be offered as a service to third party clients for a fee.
Team
-
Crispin MuriraChief Executive OfficerA champion of start-ups, Crispin is a Harvard Business School Graduate with global business experience. He has worked in well established companies as well and brings irrefutable experience in business administration. He is currently based in Atlanta, Georgia, working with a San Francisco based start-up, Copia. From its humble beginnings, Crispin championed the growth of this company to its current valuation of +$20MM USD.
-
Chief Science OfficerAs a trained immunologist has experience ranging from a post-doctorate fellow at institute Armand-Frappier to commercial analytics in the pharma industry. Armstrong has had a wealth of exposure to the molecular aspects of the immune response. He has also worked extensively with computer programming, which will facilitate discussions with the programmers who will constitute a significant portion of the early portion of the star-up activities.
Advisors
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.